image du produit
Lancet Oncology, The

S'abonner

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial - 11/08/11

Doi : 10.1016/S1470-2045(09)70162-7 
Martin E Gore, ProfMD a, ⁎ , Cezary Szczylik, ProfMD b, Camillo Porta, MD c, Sergio Bracarda, ProfMD d, Georg A Bjarnason, MD e, Stéphane Oudard, ProfMD f, Subramanian Hariharan, MD g, Se-Hoon Lee, MD h, John Haanen, ProfMD i, Daniel Castellano, MD j, Eduard Vrdoljak, MD k, Patrick Schöffski, ProfMD l, Paul Mainwaring, ProfMD m, Alejandra Nieto, MD g, Jinyu Yuan, PhD g, Ronald Bukowski, ProfMD n
a Royal Marsden Hospital NHS Trust, London, UK 
b Military Medical Institute, Oncology, Warsaw, Poland 
c IRCCS San Matteo University Hospital Foundation, Pavia, Italy 
d Azienda Ospedaliera di Perugia, Perugia, Italy 
e Sunnybrook Odette Cancer Centre, Toronto, Canada 
f Hôpital Européen Georges Pompidou, Paris, France 
g Pfizer Oncology, New York, NY, USA 
h Seoul National University Hospital, Seoul, South Korea 
i The Netherlands Cancer Institute, Amsterdam, Netherlands 
j Hospital Universitario 12 de Octubre, Madrid, Spain 
k University Hospital Split, Split, Croatia 
l University Hospitals Leuven, Leuvan Cancer Institute, Catholic University Leuven, Leuven, Belgium 
m Mater Adult Hospital, Brisbane, QLD, Australia 
n Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA 

*Correspondence to: Prof Martin E Gore, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK

Summary

Background

Results from clinical trials have established sunitinib as a standard of care for first-line treatment of advanced or metastatic renal-cell carcinoma (RCC); however, many patients, particularly those with a poorer prognosis, do not meet inclusion criteria and little is known about the activity of sunitinib in these subgroups. The primary objective of this trial was to provide sunitinib on a compassionate-use basis to trial-ineligible patients with RCC from countries where regulatory approval had not been granted.

Methods

Previously treated and treatment-naive patients at least 18 years of age with metastatic RCC were eligible. All patients received open-label sunitinib 50 mg orally once daily on schedule 4-2 (4 weeks on treatment, 2 weeks off). Safety was assessed regularly, tumour measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention-to-treat (ITT) population, which consisted of all patients who received at least one dose of sunitinib. This study is registered with ClinicalTrials.gov, NCT00130897.

Findings

As of December, 2007, 4564 patients were enrolled in 52 countries. 4371 patients were included in the modified ITT population. This population included 321 (7%) patients with brain metastases, 582 (13%) with Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher, 588 (13%) non-clear-cell RCC, and 1418 (32%) aged 65 years or more. Patients received a median of five treatment cycles (range 1–25). Reasons for discontinuation included lack of efficacy (n=1168 [27%]) and adverse events (n=362 [8%]). The most common treatment-related adverse events were diarrhoea (n=1936 [44%]) and fatigue (n=1606 [37%]). The most common grade 3–4 adverse events were fatigue (n=344 [8%]) and thrombocytopenia (n=338 [8%]) with incidences of grade 3–4 adverse events similar across subgroups. In 3464 evaluable patients, the objective response rate (ORR) was 17% (n=603), with subgroup ORR as follows: brain metastases (26 of 213 [12%]), ECOG performance status 2 or higher (29 of 319 [9%]), non-clear-cell RCC (48 of 437 [11%]) and age 65 years or more (176 of 1056 [17%]). Median progression-free survival was 10·9 months (95% CI 10·3–11·2) and overall survival was 18·4 months (17·4–19·2).

Interpretation

In a broad population of patients with metastatic RCC, the safety profile of sunitinib 50 mg once-daily (initial dose) on schedule 4-2 was manageable and efficacy results were encouraging, particularly in subgroups associated with poor prognosis who are not usually entered into clinical trials.

Funding

Pfizer Inc.

Le texte complet de cet article est disponible en PDF.

Plan


© 2009  Elsevier Ltd. Tous droits réservés.
Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 10 - N° 8

P. 757-763 - août 2009 Retour au numéro
Article précédent Article précédent
  • My Sister’s Keeper
  • Jill Jouret
| Article suivant Article suivant
  • An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
  • Francien H van Nederveen, José Gaal, Judith Favier, Esther Korpershoek, Rogier A Oldenburg, Elly MCA de Bruyn, Hein FBM Sleddens, Pieter Derkx, Julie Rivière, Hilde Dannenberg, Bart-Jeroen Petri, Paul Komminoth, Karel Pacak, Wim CJ Hop, Patrick J Pollard, Massimo Mannelli, Jean-Pierre Bayley, Aurel Perren, Stephan Niemann, Albert A Verhofstad, Adriaan P de Bruïne, Eamonn R Maher, Frédérique Tissier, Tchao Méatchi, Cécile Badoual, Jérôme Bertherat, Laurence Amar, Despoina Alataki, Eric Van Marck, Francesco Ferrau, Jerney François, Wouter W de Herder, Mark-Paul FM Vrancken Peeters, Anne van Linge, Jacques WM Lenders, Anne-Paule Gimenez-Roqueplo, Ronald R de Krijger, Winand NM Dinjens

Déjà abonné à cette revue ?